View in EDS

Therapeutic efficacy of hepatitis B surface antigen–antibodies-recombinant DNA composite in HBsAg transgenic mice

Saved in:
Bibliographic Details
Title: Therapeutic efficacy of hepatitis B surface antigen–antibodies-recombinant DNA composite in HBsAg transgenic mice
Authors: Chan, KW, Yuen, KY, Yao, X, Wen, YM, Zheng, B, Ng, MH, He, LF
Source: Vaccine. 19:4219-4225
Publisher Information: Elsevier BV, 2001.
Publication Year: 2001
Subject Terms: Cytokines - Biosynthesis, 0301 basic medicine, Hepatitis B virus, Dna, Recombinant - Immunology, T-Lymphocytes, Cytotoxic - Immunology, DNA, Recombinant, Mice, Transgenic, Antigen-Antibody Complex, Inbred C57bl, Hepatitis B Surface Antigens - Blood - Immunology, Transgenic, Mice, 03 medical and health sciences, Recombinant - Immunology, Animals, Hepatitis B Vaccines, Hepatitis B - Therapy, Hepatitis B Antibodies, T-Lymphocytes, Cytotoxic - Immunology, 0303 health sciences, Hepatitis B Surface Antigens, Immune tolerance, Dna, Therapeutic vaccine, Hepatitis B, 3. Good health, Mice, Inbred C57bl, Antigen-Antibody Complex - Immunology, Mice, Inbred C57BL, Hepatitis B Vaccines - Therapeutic Use, Hepatitis B Antibodies - Immunology, Liver - Pathology - Virology, Liver, Cytokines, T-Lymphocytes, Cytotoxic
Description: Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-gamma produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways.
Document Type: Article
Language: English
ISSN: 0264-410X
DOI: 10.1016/s0264-410x(01)00158-x
Access URL: https://pubmed.ncbi.nlm.nih.gov/11457548
https://www.sciencedirect.com/science/article/pii/S0264410X0100158X
https://www.ncbi.nlm.nih.gov/pubmed/11457548
http://www.sciencedirect.com/science/article/pii/S0264410X0100158X
http://hdl.handle.net/10722/148265
Rights: Elsevier TDM
Accession Number: edsair.doi.dedup.....1f0064d956081aaf35b3c0cbfe521a7f
Database: OpenAIRE
Description
Abstract:Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-gamma produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways.
ISSN:0264410X
DOI:10.1016/s0264-410x(01)00158-x